BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29641971)

  • 21. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study.
    Chen Q; Ning Z; Wang L; Ying H; Dong S; Zhang C; Shen X; Guo Y; Chen H; Zhu X; Shen Y; Shi W; Hua Y; Wang K; Lin J; Xu L; Chen L; Feng L; Zhang X; Xie J; Sun B; Sun Y; Gu W; Kang M; Tang Z; Chen Z; Chen Z; Liu L; Yu J; Li Z; Meng Z
    Oncotarget; 2016 Dec; 7(51):85603-85612. PubMed ID: 27811354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma.
    Dong Q; Zhang Y; Yang XH; Jing W; Zheng LQ; Liu YP; Qu XJ; Li Z
    Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):639-48. PubMed ID: 24630955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors affecting survival after pancreaticoduodenectomy for pancreatic adenocarcinoma (single center experience).
    El Nakeeb A; El Shobary M; El Dosoky M; Nabeh A; El Sorogy M; El Eneen AA; abu Zeid M; Elwahab MA
    Hepatogastroenterology; 2014; 61(133):1426-38. PubMed ID: 25436321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
    Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
    Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Factors influencing survival of patients with cancer of the pancreatic head after resection].
    Gao CT; Li HK; Li Q
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):554-7. PubMed ID: 19950708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
    J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
    Kawaida H; Fujii H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
    [No Abstract]   [Full Text] [Related]  

  • 38. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
    Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
    Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
    Zhu Z; Xu Y; Du J; Tan J; Jiao H
    J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.